HC Wainwright Forecasts Harrow’s Q4 Earnings (NASDAQ:HROW)

Harrow, Inc. (NASDAQ:HROW) – Analysts at HC Wainwright raised their Q4 2027 earnings per share (EPS) estimates for shares of Harrow in a report released on Wednesday, August 12th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings per share of $1.07 for the quarter, up from their previous forecast of $1.06. The consensus estimate for Harrow’s current full-year earnings is $0.29 per share.

Harrow (NASDAQ:HROW) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.28). The business had revenue of $70.66 million for the quarter, compared to analysts’ expectations of $69.84 million. Harrow had a negative return on equity of 31.83% and a negative net margin of 13.51%.

Other equities analysts have also recently issued research reports about the stock. Wall Street Zen cut shares of Harrow from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. BTIG Research restated a “buy” rating and set a $63.00 price objective on shares of Harrow in a research report on Tuesday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Harrow in a report on Monday, July 20th. Cantor Fitzgerald cut their target price on shares of Harrow from $91.00 to $88.00 and set an “overweight” rating for the company in a research report on Wednesday, May 13th. Finally, Zacks Research downgraded Harrow from a “hold” rating to a “strong sell” rating in a research report on Tuesday. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $69.43.

Harrow Trading Down 0.2%

Shares of HROW opened at $39.36 on Thursday. The firm’s 50 day simple moving average is $40.72 and its 200 day simple moving average is $39.92. The company has a market capitalization of $1.48 billion, a P/E ratio of -39.36 and a beta of 0.28. The company has a debt-to-equity ratio of 10.30, a current ratio of 2.48 and a quick ratio of 2.30. Harrow has a 1-year low of $28.54 and a 1-year high of $54.85.

Insider Activity at Harrow

In other Harrow news, Director Adrienne L. Graves bought 1,000 shares of the firm’s stock in a transaction that occurred on Monday, May 18th. The shares were bought at an average price of $31.07 per share, for a total transaction of $31,070.00. Following the transaction, the director directly owned 1,000 shares in the company, valued at $31,070. This trade represents a ? increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 12.80% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of HROW. Larson Financial Group LLC boosted its holdings in Harrow by 13.1% during the 4th quarter. Larson Financial Group LLC now owns 2,446 shares of the company’s stock valued at $120,000 after acquiring an additional 284 shares during the period. The Manufacturers Life Insurance Company increased its stake in Harrow by 2.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 16,547 shares of the company’s stock worth $505,000 after purchasing an additional 341 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in Harrow by 25.8% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,800 shares of the company’s stock worth $88,000 after purchasing an additional 369 shares during the period. Captrust Financial Advisors lifted its position in Harrow by 0.5% in the fourth quarter. Captrust Financial Advisors now owns 69,959 shares of the company’s stock valued at $3,428,000 after purchasing an additional 376 shares during the last quarter. Finally, Alliancebernstein L.P. lifted its position in Harrow by 1.7% in the third quarter. Alliancebernstein L.P. now owns 29,520 shares of the company’s stock valued at $1,422,000 after purchasing an additional 500 shares during the last quarter. Hedge funds and other institutional investors own 72.76% of the company’s stock.

About Harrow

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.